Compare Stocks: CRGX, DBVT, AURA, and ACRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.78 -1.4%	$5.27	$1.70 ▼ $6.51	$808.18M	0.78	1.87 million shs	666,223 shs
AURA Aura Biosciences	$7.69 +0.5%	$7.02	$4.73 ▼ $9.53	$797.49M	0.4	472,991 shs	684,462 shs
CRGX CARGO Therapeutics	$4.47	$4.49	$3.78 ▼ $4.77	$216.17M	0.3	1.43 million shs	N/A
DBVT DBV Technologies	$14.02 -0.1%	$15.21	$8.70 ▼ $26.18	$830.22M	-0.93	409,482 shs	128,541 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-2.20%	+7.84%	+27.88%	+240.00%
AURA Aura Biosciences	0.00%	-3.75%	+11.61%	-0.65%	+6.36%
CRGX CARGO Therapeutics	0.00%	0.00%	0.00%	0.00%	+0.22%
DBVT DBV Technologies	0.00%	+4.01%	-5.65%	-28.65%	+41.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.78 -1.4%	$5.27	$1.70 ▼ $6.51	$808.18M	0.78	1.87 million shs	666,223 shs
AURA Aura Biosciences	$7.69 +0.5%	$7.02	$4.73 ▼ $9.53	$797.49M	0.4	472,991 shs	684,462 shs
CRGX CARGO Therapeutics	$4.47	$4.49	$3.78 ▼ $4.77	$216.17M	0.3	1.43 million shs	N/A
DBVT DBV Technologies	$14.02 -0.1%	$15.21	$8.70 ▼ $26.18	$830.22M	-0.93	409,482 shs	128,541 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-2.20%	+7.84%	+27.88%	+240.00%
AURA Aura Biosciences	0.00%	-3.75%	+11.61%	-0.65%	+6.36%
CRGX CARGO Therapeutics	0.00%	0.00%	0.00%	0.00%	+0.22%
DBVT DBV Technologies	0.00%	+4.01%	-5.65%	-28.65%	+41.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.13	Buy	$11.50	98.96% Upside
AURA Aura Biosciences	2.25	Hold	$17.50	127.57% Upside
CRGX CARGO Therapeutics	0.00	N/A	N/A	N/A
DBVT DBV Technologies	2.71	Moderate Buy	$48.50	245.93% Upside

Current Analyst Ratings Breakdown

Latest CRGX, DBVT, AURA, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $18.00
7/17/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/14/2026	AURA Aura Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/30/2026	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/30/2026	DBVT DBV Technologies	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$47.00 ➝ $55.00
6/29/2026	AURA Aura Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	ACRS Aclaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/12/2026	AURA Aura Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/2/2026	ACRS Aclaris Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$13.00
6/1/2026	ACRS Aclaris Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	103.21	N/A	N/A	$0.89 per share	6.49
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A
DBVT DBV Technologies	$5.64M	147.21	N/A	N/A	$2.71 per share	5.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	N/A
AURA Aura Biosciences	-$106.19M	-$1.75	N/A	N/A	N/A	N/A	-73.18%	-62.00%	N/A
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	N/A
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)

Latest CRGX, DBVT, AURA, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	AURA Aura Biosciences	-$0.3750	-$0.48	-$0.1050	-$0.48	N/A	N/A
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
7/16/2026	Q2 2026	DBVT DBV Technologies	-$0.12	-$0.60	-$0.48	-$0.60	$0.90 million	$0.70 million
5/21/2026	Q1 2026	AURA Aura Biosciences	-$0.40	-$0.50	-$0.10	-$0.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
AURA Aura Biosciences	N/A	16.82	7.09
CRGX CARGO Therapeutics	N/A	12.37	12.37
DBVT DBV Technologies	N/A	3.72	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
AURA Aura Biosciences	96.75%
CRGX CARGO Therapeutics	93.16%
DBVT DBV Technologies	71.74%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
AURA Aura Biosciences	1.90%
CRGX CARGO Therapeutics	2.92%
DBVT DBV Technologies	1.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	139.82 million	133.11 million	Optionable
AURA Aura Biosciences	50	103.71 million	101.74 million	Not Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A
DBVT DBV Technologies	80	59.22 million	58.59 million	Optionable

CRGX, DBVT, AURA, and ACRS Headlines

Recent News About These Companies

DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.4% - Time to Buy?

August 10, 2026 | marketbeat.com

Perceptive Advisors LLC Invests $20.15 Million in DBV Technologies S.A. $DBVT

August 2, 2026 | marketbeat.com

DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 1, 2026 | marketbeat.com

DBV Technologies S.A. $DBVT Shares Acquired by Vivo Capital LLC

July 31, 2026 | marketbeat.com

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

July 30, 2026 | globenewswire.com

ADAR1 Capital Management LLC Acquires New Shares in DBV Technologies S.A. $DBVT

July 29, 2026 | marketbeat.com

Elmind Capital LP Makes New Investment in DBV Technologies S.A. $DBVT

July 28, 2026 | marketbeat.com

DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap

July 26, 2026 | seekingalpha.com

DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside

July 23, 2026 | seekingalpha.com

DBV Technologies (NASDAQ:DBVT) Sees Large Volume Increase - Should You Buy?

July 21, 2026 | marketbeat.com

HC Wainwright Analysts Decrease Earnings Estimates for DBVT

July 21, 2026 | marketbeat.com

DBV Technologies (NASDAQ:DBVT) Shares Gap Down - Should You Sell?

July 20, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and Kalaris Therapeutics (KLRS)

July 18, 2026 | theglobeandmail.com

Dorsey Wright & Associates Purchases New Shares in DBV Technologies S.A. $DBVT

July 18, 2026 | marketbeat.com

DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales

July 17, 2026 | globenewswire.com

DBV Technologies Announces the Filing of its 2026 Half-Year Report ? Conditions for Accessing or Consulting the Report

July 16, 2026 | tmcnet.com

DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript

July 16, 2026 | seekingalpha.com

DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report

July 16, 2026 | globenewswire.com

DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

July 16, 2026 | globenewswire.com

DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026

July 14, 2026 | globenewswire.com

DBV Technologies Stock Dividends | NASDAQ:DBVT | Benzinga

July 8, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CRGX, DBVT, AURA, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$5.78 -0.08 (-1.37%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$5.82 +0.04 (+0.69%)

As of 08/14/2026 07:34 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aura Biosciences NASDAQ:AURA

$7.69 +0.04 (+0.52%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$7.70 +0.00 (+0.07%)

As of 08/14/2026 07:34 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

CARGO Therapeutics NASDAQ:CRGX

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

DBV Technologies NASDAQ:DBVT

$14.02 -0.01 (-0.07%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$14.04 +0.02 (+0.14%)

As of 08/14/2026 04:20 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRGX, DBVT, AURA, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRGX, DBVT, AURA, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRGX, DBVT, AURA, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CRGX, DBVT, AURA, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Aura Biosciences NASDAQ:AURA

CARGO Therapeutics NASDAQ:CRGX

DBV Technologies NASDAQ:DBVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRGX, DBVT, AURA, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRGX, DBVT, AURA, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRGX, DBVT, AURA, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CRGX, DBVT, AURA, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Aura Biosciences NASDAQ:AURA

CARGO Therapeutics NASDAQ:CRGX

DBV Technologies NASDAQ:DBVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools